China Tian Yuan Healthcare Group Limited (0557) AI Stock Analysis

• Market Cap: HK$235.40M
• Dividend Yield: N/A
• Average Volume (3M): 3.33K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.73
• Revenue Growth: -43.78%
• EPS Growth: -118.13%
• Country: HK
• Employees: 34
• Sector: Healthcare
• Sector Strength: 45
• Industry: Travel Lodging
• EPS (TTM): >-0.01
• Shares Outstanding: 398,979,520
• 10 Day Avg. Volume: 1,000
• 30 Day Avg. Volume: 3,326
• PEG Ratio: -0.05
• Price to Book (P/B): 1.07
• Price to Sales (P/S): 7.73
• P/FCF Ratio: 19.44
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 48 Neutral
• Price Target: HK$0.69 ▼(-1.00% Downside)
• Action: Reiterated Date: 01/15/26
• Date: Action: Reiterated 01/15/26

The score is primarily held down by weak financial performance driven by declining revenue and ongoing losses. Technicals are mixed-to-modestly supportive with price above key short-term averages but negative MACD. Valuation remains constrained due to loss-making earnings (negative P/E) and no dividend yield data.

Positive Factors

Diversified Business Model

China Tian Yuan’s mix of traditional Chinese medicine, Western pharmaceuticals and healthcare services, plus partnerships with hospitals and clinics, creates diversified revenue streams and distribution channels. This reduces single-product dependence, supporting resilience and cross-selling opportunities over months.

Conservative Leverage

A relatively low debt-to-equity position gives the company financial flexibility and lower fixed interest burdens. This conservative leverage supports the ability to fund operations or investments and absorb short-term shocks without immediate refinancing pressure, helping preserve strategic optionality.

Improving Cash Generation

Reported positive operating cash flow and noted improvement in free cash flow indicate core operations can generate cash despite accounting losses. Durable cash generation supports working capital, selective capex or R&D funding and reduces near-term dependence on external financing if the trend continues.

Negative Factors

Sharp Revenue Decline

A roughly 44% year-over-year revenue decline signals material loss of scale or demand and weakens market position. Sustained top-line contraction compresses operating leverage, reduces ability to absorb fixed costs, and undermines capacity to invest in product development or distribution over the medium term.

Persistent Profitability Issues

Consistent negative EBIT and net income reflect structural profitability problems rather than one-off items. Ongoing losses erode retained earnings, limit reinvestment, may force recurring cost containment or capital raises, and constrain management’s ability to execute strategic growth plans sustainably.

Eroding Shareholders' Equity

A notable decline in shareholders’ equity from sustained losses weakens the capital buffer and financial resilience. Reduced equity lowers borrowing capacity, increases vulnerability to adverse shocks, and can restrict strategic options such as M&A or larger R&D investments until profitability and equity are rebuilt.

China Tian Yuan Healthcare Group Limited Business Overview & Revenue Model

Company Description

China Tian Yuan Healthcare Group Limited, an investment holding company, provides healthcare related services in Hong Kong, Korea, and the People's Republic of China. It operates through Investment Holding, Healthcare, Money Lending and Related Business, and Hospitality segments. The company offers procurement, marketing, and management services to the medical industry; and plastic surgery services, as well as licenses trademarks. It also invests in equity investments and marketable equitable equity mutual funds; offers loans and related services; introduces lenders and borrowers; and provides procurement services to hospitality industry. The company was formerly known as City e-Solutions Limited and changed its name to China Tian Yuan Healthcare Group Limited in November 2017. The company was incorporated in 1990 and is based in Wan Chai, Hong Kong. China Tian Yuan Healthcare Group Limited is a subsidiary of Tian Yuan Manganese Limited.

How the Company Makes Money

The company generates revenue through multiple streams, primarily by selling its pharmaceutical products and healthcare services. Key revenue streams include the sale of prescription and over-the-counter medications, traditional Chinese medicine products, and health supplements. Additionally, China Tian Yuan Healthcare Group has established partnerships with hospitals, clinics, and healthcare providers to enhance its distribution network and expand its market reach. These collaborations not only bolster sales but also facilitate the integration of its products into broader healthcare systems. The company may also engage in research and development activities funded by government grants or partnerships, further contributing to its financial performance.

China Tian Yuan Healthcare Group Limited Financial Statement Overview

Summary

Income statement is weak (declining revenue and persistent EBIT/net losses), partially offset by a comparatively stronger balance sheet (low leverage and solid equity ratio) and improved but still volatile cash generation.

Income Statement

The company has seen a consistent decline in revenue over the years, with significant negative figures in EBIT and net income indicating ongoing profitability issues. Gross profit margin is high but overshadowed by persistent losses, suggesting challenges in controlling operating expenses.

Balance Sheet

The company's debt-to-equity ratio is relatively low, indicating conservative leverage. However, the significant decline in stockholders' equity due to consistent losses raises concerns. The equity ratio remains strong, showing a robust capital structure despite financial challenges.

Cash Flow

Positive operating cash flow in recent years is a positive sign, suggesting some operational efficiency. However, free cash flow has been volatile, and prior negative figures highlight potential issues in managing cash effectively. Improvement in free cash flow is notable but needs sustainability.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	26.41M	26.84M	45.23M	54.22M	94.59M	56.34M
Gross Profit	21.80M	14.91M	24.98M	34.83M	71.31M	37.57M
EBITDA	-30.06M	-27.22M	-15.79M	-13.08M	-2.89M	-102.17M
Net Income	-46.01M	-34.24M	-15.48M	-29.04M	-16.85M	-65.10M
Balance Sheet
Total Assets	263.11M	260.93M	302.95M	333.55M	376.40M	381.30M
Cash, Cash Equivalents and Short-Term Investments	28.29M	27.05M	26.73M	31.60M	77.89M	71.08M
Total Debt	40.80M	45.97M	45.91M	51.13M	59.66M	55.06M
Total Liabilities	90.61M	84.98M	87.77M	91.52M	92.35M	83.91M
Stockholders Equity	193.98M	194.68M	230.26M	224.30M	256.25M	267.53M
Cash Flow
Free Cash Flow	7.17M	10.67M	4.51M	-31.71M	14.86M	49.20M
Operating Cash Flow	7.18M	10.69M	5.10M	-30.36M	16.32M	49.54M
Investing Cash Flow	-4.50K	-3.00K	364.00K	-1.23M	-1.42M	-11.22M
Financing Cash Flow	-10.88M	-10.85M	-8.77M	-12.49M	-7.22M	-2.54M

China Tian Yuan Healthcare Group Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.70
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0557, the sentiment is Negative. The current price of 0.7 is above the 20-day moving average (MA) of 0.69, above the 50-day MA of 0.70, and below the 200-day MA of 0.79, indicating a bearish trend. The MACD of -0.02 indicates Positive momentum. The RSI at 37.39 is Neutral, neither overbought nor oversold. The STOCH value of 33.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:0557.

China Tian Yuan Healthcare Group Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
0219	61 Neutral	HK$388.83M	-0.56	-4.72%	―	3.58%	-91.61%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
0617	49 Neutral	HK$212.89M	-0.13	-19.01%	―	-2.75%	-17.31%
0557	48 Neutral	HK$235.40M	-50.66	-15.15%	―	-43.78%	-118.13%
0355	47 Neutral	HK$235.04M	-0.13	-18.68%	―	-3.51%	-15.27%
0199	41 Neutral	HK$1.06B	-0.41	-18.98%	―	798.63%	56.55%
0078	40 Neutral	HK$494.33M	-0.21	-29.62%	―	-0.60%	34.74%

China Tian Yuan Healthcare Group Limited Corporate Events

China Tian Yuan Healthcare Details Valuation and Compliance for 70% Stake Acquisition

China Tian Yuan Healthcare Group Limited has provided further details on its previously announced acquisition of a 70% equity interest in a target company for RMB2.1 million, confirming that the valuation of the target as at 31 October 2025 was set at RMB3.07 million using a discounted cash flow method under an income-based approach. The company emphasized compliance with Hong Kong Listing Rules by disclosing that its auditor, Crowe (HK) CPA Limited, has verified the arithmetical accuracy of the discounted cash flow calculations, and the board has confirmed, after due and careful enquiry, the reasonableness of the profit forecasts used in the valuation; the independent valuer selected the income-based approach as the final valuation basis due to the lack of comparable market data and the target’s predictable profitability, underscoring the transaction’s alignment with regulatory requirements and its reliance on the target’s future earnings potential to support the deal pricing.

The most recent analyst rating on (HK:0557) stock is a Hold with a HK$0.70 price target. To see the full list of analyst forecasts on China Tian Yuan Healthcare Group Limited stock, see the HK:0557 Stock Forecast page.

China Tian Yuan Healthcare Seeks Listing Rules Waiver on Acquisition Disclosure

China Tian Yuan Healthcare Group Limited has applied for a waiver from strict compliance with Rule 14.60A of the Hong Kong Listing Rules to extend the deadline for publishing information related to its proposed acquisition of a 70% equity interest in a target company for RMB2.1 million. The extension, sought to move the disclosure deadline from 22 January 2026 to 30 January 2026, is needed to allow the company’s auditors additional time to prepare and finalize a letter regarding the profit forecast of the target company; the acquisition remains subject to conditions precedent under the equity transfer agreement, and the company cautions that the transaction may or may not proceed, advising shareholders and potential investors to exercise caution.

The most recent analyst rating on (HK:0557) stock is a Hold with a HK$0.81 price target. To see the full list of analyst forecasts on China Tian Yuan Healthcare Group Limited stock, see the HK:0557 Stock Forecast page.

China Tian Yuan Healthcare Accelerates 70% Stake Acquisition via Supplemental Agreement

China Tian Yuan Healthcare Group Limited has signed a supplemental agreement to revise the terms of its planned acquisition of a 70% equity interest in a target company for RMB2.1 million, deciding not to proceed with a previously planned capital reduction at the target and instead accelerating completion of the equity transfer while ensuring full payment of the outstanding capital contribution by the purchaser. The parties have brought forward the transaction completion deadline to 31 January 2026 to avoid delays linked to the capital reduction process, with reciprocal indemnity and liquidated damages provisions introduced to protect both sides; the group says the new timetable is intended to secure rapid integration of the target’s core team, maintain operational continuity and capture a key industry peak season beginning in March, although completion remains subject to outstanding conditions and may still not proceed.

The most recent analyst rating on (HK:0557) stock is a Hold with a HK$1.00 price target. To see the full list of analyst forecasts on China Tian Yuan Healthcare Group Limited stock, see the HK:0557 Stock Forecast page.

China Tian Yuan Healthcare to Acquire 70% Stake in Healthcare Target for RMB2.1 Million

China Tian Yuan Healthcare Group Limited, through an indirect wholly owned subsidiary, has agreed to acquire a 70% equity interest in an unnamed target company for RMB2.1 million, subject to conditions precedent under an equity transfer agreement signed on 31 December 2025. Following completion, the target will become an indirect non-wholly owned subsidiary, with the remaining 30% retained by the two vendors, and its financial results will be consolidated into the group’s accounts, marking a modest but strategic expansion of the group’s healthcare portfolio. The transaction has been classified as a discloseable transaction under Hong Kong listing rules, triggering notification and announcement requirements, and the company has indicated it will issue a further announcement based on a valuation that uses a discounted cash flow method, while cautioning investors that completion is still conditional and may not proceed.

The most recent analyst rating on (HK:0557) stock is a Hold with a HK$1.00 price target. To see the full list of analyst forecasts on China Tian Yuan Healthcare Group Limited stock, see the HK:0557 Stock Forecast page.

China Tian Yuan Healthcare Clarifies Internal Reshuffle of Controlling Shareholder

China Tian Yuan Healthcare Group Limited announced an internal reorganisation of its controlling shareholder’s shareholding structure, under which Ningxia Tianyuan Manganese Industry Group Co., Ltd. transferred its 100% equity interest in Tian Yuan Manganese to Ningxia TY Holding at nil consideration. Following the restructuring, Tian Yuan Manganese continues to hold approximately 66.69% of the company’s issued shares, while ultimate control remains with Mr. Jia Tianjiang via Ningxia TY Group, and the board expects no material impact on the company’s management or operations. As Ningxia TY Holding indirectly acquired about 66.69% of the company’s shares through this internal transfer, it obtained a waiver from the obligation to make a general offer under Hong Kong’s Takeovers Code, underscoring that the transaction is a technical change in the shareholding chain rather than a shift in effective control, and therefore is not expected to alter the position of public shareholders or other stakeholders.

The most recent analyst rating on (HK:0557) stock is a Hold with a HK$1.00 price target. To see the full list of analyst forecasts on China Tian Yuan Healthcare Group Limited stock, see the HK:0557 Stock Forecast page.